AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04894409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mouthwash and nose rinse with the AgNPs solution
Description: The experimental group was instructed to do mouthwash and nose rinse with the AgNPs solution for the prevention of SARS-CoV-2 infection in health workers
Study NCT04894409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwashes and nose rinse in a conventional way
Description: The control group was instructed to do mouthwashes and nose rinse in a conventional way
Study NCT02359539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regenerative therapy
Description: Periosteal pedicle, Platelets rich fibrin
Study NCT04893941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM310
Description: IL-4Rα monoclonal antibody
Study NCT04893941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03236363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI-da10! active breaks
Description: MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
Study NCT03236363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI-da10! integrated physical activity
Description: MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate \<150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
Study NCT01652963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reed and Clements Training Task
Description: see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
Study NCT05531617 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Study groups Intubated with Macintosh or cmac video laryngoscopes
Study NCT01886534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Heart Failure Discharge Summary to Primary Care Physicians©
Description: At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
Study NCT01886534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized education sessions
Description: Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
Study NCT01368120 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm CHG™
Description: Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
Study NCT01368120 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Silicone Vehicle Control Dressing
Description: Polyurethane film with silicone adhesive dressing, without antimicrobials
Study NCT01886534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure Diuretic Decision Support Tool for Patient Self Management©
Description: Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
Study NCT00002784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Filgrastim 10 mg/kg/d sc for 6 days after randomization.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMF regimen
Description: Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
Study NCT01886534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital talking scale
Description: Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
Study NCT01886534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
Study NCT01886534 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
Study NCT01107028 — intervention group
Intervention type: OTHER
Intervention: Standard pulmonary rehabilitation program
Description: At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
Study NCT04221594 — intervention group
Intervention type: PROCEDURE
Intervention: Invasive Cardiac Catheterization (ICA)
Description: Invasive functional measurements will be performed to assess the functional significance of specific lesions by means of FFR and CFR, and to test the presence of microvascular disease by means of IMR in all vessels for which the procedures are feasible. In summary, a 5- to 7-F guide catheter without side holes is used to engage the coronary artery and a pressure-temperature sensor-tipped guidewire introduced. The pressure sensor is positioned at the distal segment of a target vessel, and intracoronary nitroglycerine (100-200 mg) administered before each measurement. The best systolic and diastolic phase (located between 30-50%, and 60-75% of the cardiac cycle) will be selected for successive processing as it allows a relative motion free visualization of the main vessels and the myocardium.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin hydrochloride
Description: Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesna
Description: MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methotrexate
Description: Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Tamoxifen 20mg daily for 5 years or until relapse.
Study NCT00002784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Description: Tamoxifen 20mg daily for 5 years or until relapse.
Study NCT00002784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
Study NCT00002784 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy
Description: Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
Study NCT00002784 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET electron therapy
Description: Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
Study NCT00398827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT00398827 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03420417 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal pressure measurement
Description: Use of a nasogastric tube equipped with esophageal balloon to assess respiratory mechanics
Study NCT03805906 — intervention group
Intervention type: PROCEDURE
Intervention: L5 Dorsal ramus block
Description: Ultrasound-guided L5 dorsal ramus block
Study NCT00884533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosi XR
Description: Rosi XR
Study NCT00884533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00884533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04221594 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary Computed Tomographic Angiogram (CCTA)
Description: Fasting patients will undergo a test for coronary calcium by CT; calcium scoring analysis will be done post image data acquisition using the manufacturer's software. Nitroglycerine will be administered in all patients (sublingual administration prior to CCTA initiation). CT acquisitions will be prospectively ECG-gated (30-80% of the cardiac cycle). The acquisition begins with a scout scan to identify the borders of the heart to minimize the field of view and exposure to the patient. A bolus of 60 mL nonionic contrast agent is then injected followed by 60 mL of saline at a rate of 4 mL/s to enhance signal from coronary arteries and blood chambers. In case of irregular heart rate, beta-blockers can be provided to keep optimal heart rate \~65-70 bpm. Trans-axial images are reconstructed by means of a filtered back-projection algorithm.
Study NCT04221594 — intervention group
Intervention type: PROCEDURE
Intervention: Dynamic Cardiac Positron Emission Tomography (dPET)
Description: Patients will be asked to fast for 24 hours prior to the test. Before the resting perfusion phase, a single low-dose CT-based transmission scan is acquired for attenuation correction (AC) of all subsequent acquisitions. AC-CT images are automatically registered to the perfusion images, visually verified and manually corrected if necessary. Resting perfusion imaging started with the intravenous injection of a single bolus of 82Rb. Pharmacological stress imaging is obtained after adenosine infusion (140 μg/kg/min) through a peripheral vein, followed by a second dose of 82Rb. Image reconstruction is achieved by means of ordered subset expectation maximization (OSEM) iterative method. The hemodynamic responses to rest/stress tests are collected in terms of mean heart rate, mean blood systolic pressures and diastolic at rest and stress. Dynamic, gated and ungated trans-axial reconstructions are saved in DICOM format for further analysis and processing.
Study NCT01132417 — intervention group
Intervention type: DRUG
Intervention: In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance
Description: studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
Study NCT04523480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testopel 75mg Drug Implant
Description: 75 mg Testosterone pellets administered subcutaneously.
Study NCT00884533 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00884533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400mg single dose
Study NCT00488072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: 15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.
Study NCT00488072 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet by mouth daily.
Study NCT03467607 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tidal volume ventilation
Description: low tidal volume ventilation
Study NCT00570414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask airway
Description: Airway management by the use of the flexible, reinforced laryngeal mask airway
Study NCT00570414 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Description: Airway management by the use of endotracheal tube
Study NCT00880373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
Study NCT00880373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo three times daily for 4 days
Study NCT00880373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diamorphine or Morphine
Description: Diamorphine or Morphine by PCA
Study NCT00880373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diamorphine or Morphine
Description: Diamorphine or Morphine by PCA
Study NCT03003611 — intervention group
Intervention type: PROCEDURE
Intervention: hypnose sedation
Description: Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia
Study NCT03003611 — intervention group
Intervention type: PROCEDURE
Intervention: general anesthesia
Description: Patient will be anesthetized with a classical general anesthesia
Study NCT03149510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: Participants will use the mobile application daily to assess heart failure symptoms.
Study NCT04523480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testopel 100mg Drug Implant
Description: 100 mg Testosterone pellets administered subcutaneously.
Study NCT04523480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testopel 200mg Drug Implant
Description: 200 mg Testosterone pellets administered subcutaneously.
Study NCT02726386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ND0612
Description: ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
Study NCT03168906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
Study NCT03168906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline bag
Study NCT03458364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High-flow nasal cannula (HFNC) oxygen therapy is a recent technique delivering a high flow of heated and humidified gas. HFNC is simpler to use and apply than noninvasive ventilation (NIV) and appears to be a good alternative treatment for hypoxemic acute respiratory failure (ARF). HFNC is better tolerated than NIV, delivers high fraction of inspired oxygen (FiO2), generates a low level of positive pressure and provides washout of dead space in the upper airways, thereby improving mechanical pulmonary properties and unloading inspiratory muscles during ARF.
Study NCT03458364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive ventilation
Description: Non-invasive ventilation (NIV) is the use of airway support administered through a face (nasal) mask instead of an endotracheal tube. Inhaled gases are given with positive end-expiratory pressure often with pressure support or with assist control ventilation at a set tidal volume and rate. Numerous studies have shown this technique to be as effective as, and better tolerated than, intubation and mechanical ventilation in patients with exacerbations of COPD
Study NCT02707887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LETS ACT
Description: The Life Enhancement Treatment for Substance Use (LETS ACT)
Study NCT02707887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LETS ACT-SE
Description: Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
Study NCT02707887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will receive the treatment typically provided to patients at the substance use treatment facility.
Study NCT02707887 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Participants will receive the treatment typically provided to patients at the substance use treatment facility.
Study NCT03544840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Home Program
Description: On the first day of the intervention phase (B), the PI will deliver the dynamic standing home program device (Upsee) to the parent and child. The PI will provide training and education to the parent on the device and home program. At the weekly visit to score outcome measures, the PI will check the fit of the devices, ensure compliance, and answer any questions about the home program. Parents will be encouraged to use the device with their child 5 days per week, 30 minutes per day. Parents will keep a daily log sheet to record duration of device use, activities performed, and subjective observations of the child during the intervention (Appendix K). The PI will collect these log sheets each week. The baseline phases (A1 and A2) will last 4 weeks and the intervention phase (B) will last 6 weeks. Part 2 of the study is expected to last 14 weeks.
Study NCT04108962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasenra, 30 Mg/mL Subcutaneous Solution
Description: Anti-IL5 receptor alpha monoclonal antibody
Study NCT03866928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stiripentol
Description: 1500 mg of stiripentol b.i.d.
Study NCT01422486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezatiostat hydrochloride (Telintra®)
Description: Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
Study NCT03267654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib combined with chemotherapy
Description: Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.~Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit.
Study NCT03267654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib combined with apatinib
Description: gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.~Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death.
Study NCT03267654 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gefitinib single agent
Description: Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.